ketanserin has been researched along with Akinetic-Rigid Variant of Huntington Disease in 1 studies
Ketanserin: A selective serotonin receptor antagonist with weak adrenergic receptor blocking properties. The drug is effective in lowering blood pressure in essential hypertension. It also inhibits platelet aggregation. It is well tolerated and is particularly effective in older patients.
ketanserin : A member of the class of quinazolines that is quinazoline-2,4(1H,3H)-dione which is substituted at position 3 by a 2-[4-(p-fluorobenzoyl)piperidin-1-yl]ethyl group.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cross, AJ | 1 |
| Crow, TJ | 1 |
| Peters, TJ | 1 |
1 other study available for ketanserin and Akinetic-Rigid Variant of Huntington Disease
| Article | Year |
|---|---|
Cortical neurochemistry in Alzheimer-type dementia.
Topics: Aged; Alzheimer Disease; Cerebral Cortex; Cholinergic Fibers; Endoplasmic Reticulum; Female; Golgi A | 1986 |